Epigral Ltd

Epigral, a midcap chemicals company, saw a significant decline on February 14, 2025, reversing a brief period of gains. The stock underperformed its sector and is trading below multiple moving averages, indicating a bearish trend despite a monthly gain that contrasts with the broader market's performance.

Epigral, a midcap chemicals company, has recently seen a change in its evaluation, reflecting a complex financial landscape. The firm reported strong third-quarter performance with a 22.1% return on capital employed and notable growth in net sales and operating profit, despite concerns over its valuation metrics.

Epigral, a midcap chemicals company, has experienced notable trading activity, outperforming its sector significantly. The stock has shown a strong upward trend over the past three days, with a substantial total return. Its performance contrasts with the broader market, highlighting its robust position within the industry.

Epigral, a midcap chemicals company, has recently adjusted its evaluation following strong third-quarter performance in FY24-25, with net sales growing by 23.14% and operating profit by 19.71%. The company has shown consistent positive results over four quarters and maintains a solid debt-equity ratio of 0.64.

Epigral, a midcap chemicals company, has experienced notable stock activity, achieving consecutive gains and outperforming its sector. The stock's current price exceeds several moving averages, indicating a positive short-term trend, while its month-long performance contrasts with a decline in the broader market, suggesting potential for recovery.

Epigral, a midcap chemicals company, has experienced notable stock activity, achieving consecutive gains and outperforming its sector. The stock's current price exceeds several moving averages, indicating a positive short-term trend, while its month-long performance contrasts with a decline in the broader market, suggesting potential for recovery.

Epigral, a midcap chemicals company, has experienced notable stock activity, achieving consecutive gains and outperforming its sector. The stock's current price exceeds several moving averages, indicating a positive short-term trend, while its month-long performance contrasts with a decline in the broader market, suggesting potential for recovery.

Epigral, a midcap chemicals company, faced a significant decline in stock performance, underperforming its sector amid broader market challenges. The stock is trading below multiple moving averages, indicating a sustained downward trend, and has seen an 8.74% drop over the past month, contrasting with the smaller decline of the Sensex.

Epigral has announced its financial results for the quarter ending December 2024, showcasing a record operating profit of Rs 182.51 crore and a profit after tax of Rs 103.63 crore. However, challenges persist with a low operating profit to interest ratio and decreased cash reserves, indicating liquidity concerns.

Epigral, a midcap chemicals company, has demonstrated notable trading activity, outperforming its sector despite a general decline. The stock reached an intraday high and exhibited high volatility. While it has seen a slight decline over the past month, it remains above several key moving averages, indicating potential recovery trends.

Epigral, a midcap chemicals company, has recently adjusted its evaluation, reflecting a reassessment of its market position. The firm reported a 74.50% return over the past year and a 31.4% increase in profits, despite a 7.65% decline in operating profit. Its financial structure remains solid with a low debt-equity ratio.

Epigral, a midcap chemicals company, experienced a significant rise on January 14, 2025, after two days of losses. Despite this uptick, the stock remains below key moving averages and has declined over the past month, contrasting with broader market trends. It has been identified as a Hidden Turnaround since April 2024.

Epigral, a midcap chemicals company, has recently adjusted its evaluation based on financial metrics and market position. The firm reported a 6.37% annual net sales growth for Q2 FY24-25, with first-half sales reaching Rs 1,277.26 crore. Despite a decline in operating profit, Epigral has shown consistent positive results and strong market performance.

Epigral, a midcap chemicals company, has encountered significant stock performance challenges, with a notable decline over recent days. The stock has shown high volatility and is currently trading below multiple moving averages, reflecting a bearish trend. Over the past month, it has experienced a substantial decline compared to broader market indices.

Epigral, a midcap player in the chemicals sector, has undergone a revision in its score following a notable decline in performance. The stock has been added to MarketsMOJO's list, reflecting its current market challenges. Investors are advised to monitor its trajectory closely amid these developments.

Epigral Ltd has seen a revision in its score following a notable gain of 5.36% on January 7, 2025, reversing a two-day decline. Despite this uptick, the stock's one-month performance remains down. Epigral has been added to MarketsMOJO's list, reflecting its evolving market position in the chemicals industry.

Epigral, a midcap player in the chemicals industry, has undergone a revision in its stock evaluation by MarketsMOJO, reflecting a notable shift in its standing. Despite impressive growth metrics, including a significant annual return and healthy profit increases, concerns over valuation persist. The stock has been added to MarketsMOJO's list, underscoring its strong market performance.